®, the first FDA-approved digital medicine.
Bill currently serves as Chairman of the Board of Directors of OPDC and is also the Chairman of the Board of the Sozosei Foundation, a newly established Otsuka charitable organization focused on decriminalization of mental illness. He serves on the boards of Excision BioTherapeutics, Saama and Annexon Biosciences and is Trustee of the non-profit Internet2. He is Board Chair Emeritus of the Sphinx Organization, which advocates for parity and inclusion in the arts.
“Bill is an eminent figure in the biopharmaceutical community with a proven track record of advancing therapies through clinical development, regulatory approval and commercialization. His appointment demonstrates our ambition to establish Decibel at the forefront of innovation in treatments to restore and improve hearing and balance,” said Laurence Reid, Ph.D., Chief Executive Officer. “Bill is passionate about delivering life-changing therapies in areas of unmet medical
26 May 2021 | 09:14am
StockMarketWire.com - Skin health focused SkinBioTherapeutics said a study of consumers using one of its food supplements had garnered highly positive feedback.
The AxisBiotix-Ps powered supplement was designed to modulate the immune system by harnessing the gut-skin axis, to address problems associated with sensitive skin conditions such as psoriasis.
A 56-day self-managed consumer study commenced in February with 76% of participants that self-identified as suffering from psoriasis reporting that their skin felt less itchy.
Additionally, 75% reported that their skin appeared less red, 73% reported that their skin felt less irritable and 65% reported that they had fewer flaky patches of skin.